We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. is set to begin vaccinations of healthcare workers and long-term care facility residents with the nation’s second authorized COVID-19 vaccine today, following the landmark authorization Friday of Moderna’s highly effective shot and its subsequent rollout over the weekend. Read More
Novartis believes the drug can become the first complement pathway inhibitor to slow disease progression in several complement-driven diseases. Read More
GlaxoSmithKline has received FDA approval for Benlysta (belimumab) to treat active lupus nephritis, a serious inflammation of the kidneys that appears in about four in 10 patients with the most common form of lupus. The inflammation can lead to end-stage kidney disease, requiring dialysis or a kidney transplant. Read More
The FDA’s vaccines advisory committee voted almost unanimously on Thursday in favor of Emergency Use Authorization (EUA) for Moderna’s COVID-19 vaccine, with all but one abstaining member supporting clearance, and authorization is widely expected to come today. Read More
Novartis believes iptacopan has the potential to become the first complement pathway inhibitor to slow disease progression in several diseases. Read More
The FDA’s vaccines advisory committee will meet tomorrow to discuss Moderna’s two-dose COVID-19 vaccine and is expected to vote in favor of Emergency Use Authorization (EUA) from the agency. Read More